Bevacizumab Biosimilar Approved in Europe

February 19, 2019 – The European Commission has approved PF-06439535, a bevacizumab biosimilar for the treatment of patients with metastatic carcinoma of the colon or rectum, metastatic breast cancer, unresectable advanced, metastatic, or recurrent non–small cell lung cancer (NSCLC), advanced and/or metastatic renal cell cancer, and persistent recurrent or metastatic carcinoma of the cervix. “We are proud that Zirabev was approved today as our second oncology … (leggi tutto)